Treatment of hyperandrogenic states in women.
Hyperandrogenic states have to be treated according to their etiology. But, idiopathic hirsutism represents the majority of observed cases. Its pathophysiology is still under discussion. The ovary and/or adrenal origin has led to various treatments with corticoids or combined estrogen-progestogen preparations. However, practical problems are different. After ruling out a tumoral process or mild congenital adrenal hyperplasia, a rational and efficient treatment must be proposed. It has now become possible with the use of both antiandrogen and antigonadotropin drugs. Cyproterone acetate is the best therapeutic agent because of its antiandrogen, antigonadotropin and progestogen properties. Because of its antiestrogen effects, cyproterone acetate must be used in combination with estrogens as a substitutive therapy to permit regular bleeding.
D000728:Androgens / Q000096:biosynthesis*; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006628:Hirsutism / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010048:Ovarian Cysts / Q000378:metabolism; D013739:Testosterone / Q000096:biosynthesis
D000728:Androgens; D004967:Estrogens; D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone